Therefore, reliance on a single IL-17, IL-23 and TNF-α inhibitor may not sufficiently address the diverse critical pathways involved in psoriasis, potentially resulting in suboptimal outcomes in targeted therapy. The gene discussed is IL17A; the disease is psoriasis.